GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00610417 | Liver | NAFLD | regulation of wound healing | 39/1882 | 134/18723 | 5.52e-10 | 1.28e-07 | 39 |
GO:00420607 | Liver | NAFLD | wound healing | 84/1882 | 422/18723 | 6.56e-10 | 1.37e-07 | 84 |
GO:0030193 | Liver | NAFLD | regulation of blood coagulation | 24/1882 | 66/18723 | 9.30e-09 | 1.26e-06 | 24 |
GO:1900046 | Liver | NAFLD | regulation of hemostasis | 24/1882 | 68/18723 | 1.84e-08 | 2.09e-06 | 24 |
GO:19030347 | Liver | NAFLD | regulation of response to wounding | 41/1882 | 167/18723 | 4.70e-08 | 4.58e-06 | 41 |
GO:0050818 | Liver | NAFLD | regulation of coagulation | 24/1882 | 71/18723 | 4.80e-08 | 4.60e-06 | 24 |
GO:00316677 | Liver | NAFLD | response to nutrient levels | 85/1882 | 474/18723 | 8.23e-08 | 7.09e-06 | 85 |
GO:00075994 | Liver | NAFLD | hemostasis | 49/1882 | 222/18723 | 9.23e-08 | 7.59e-06 | 49 |
GO:00075964 | Liver | NAFLD | blood coagulation | 48/1882 | 217/18723 | 1.16e-07 | 8.81e-06 | 48 |
GO:00508174 | Liver | NAFLD | coagulation | 48/1882 | 222/18723 | 2.40e-07 | 1.61e-05 | 48 |
GO:00458617 | Liver | NAFLD | negative regulation of proteolysis | 66/1882 | 351/18723 | 4.02e-07 | 2.58e-05 | 66 |
GO:0072376 | Liver | NAFLD | protein activation cascade | 8/1882 | 12/18723 | 3.51e-06 | 1.40e-04 | 8 |
GO:0072378 | Liver | NAFLD | blood coagulation, fibrin clot formation | 7/1882 | 10/18723 | 9.36e-06 | 3.02e-04 | 7 |
GO:00075844 | Liver | NAFLD | response to nutrient | 36/1882 | 174/18723 | 2.06e-05 | 5.78e-04 | 36 |
GO:0002526 | Liver | NAFLD | acute inflammatory response | 26/1882 | 112/18723 | 3.68e-05 | 9.23e-04 | 26 |
GO:00513467 | Liver | NAFLD | negative regulation of hydrolase activity | 62/1882 | 379/18723 | 8.11e-05 | 1.66e-03 | 62 |
GO:00525477 | Liver | NAFLD | regulation of peptidase activity | 72/1882 | 461/18723 | 1.03e-04 | 2.03e-03 | 72 |
GO:00525487 | Liver | NAFLD | regulation of endopeptidase activity | 67/1882 | 432/18723 | 2.17e-04 | 3.70e-03 | 67 |
GO:00508787 | Liver | NAFLD | regulation of body fluid levels | 60/1882 | 379/18723 | 2.61e-04 | 4.23e-03 | 60 |
GO:00487327 | Liver | NAFLD | gland development | 67/1882 | 436/18723 | 2.83e-04 | 4.53e-03 | 67 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SERPINC1 | SNV | Missense_Mutation | | c.604N>A | p.Leu202Ile | p.L202I | P01008 | protein_coding | tolerated(0.18) | probably_damaging(0.986) | TCGA-A2-A0YJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
SERPINC1 | SNV | Missense_Mutation | novel | c.1142C>G | p.Ser381Cys | p.S381C | P01008 | protein_coding | deleterious(0) | benign(0.148) | TCGA-A2-A4S3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SERPINC1 | SNV | Missense_Mutation | | c.147N>A | p.Met49Ile | p.M49I | P01008 | protein_coding | tolerated(0.16) | benign(0.003) | TCGA-BH-A0BR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SERPINC1 | SNV | Missense_Mutation | | c.32C>T | p.Ser11Phe | p.S11F | P01008 | protein_coding | deleterious_low_confidence(0.03) | benign(0.094) | TCGA-BH-A0E1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
SERPINC1 | SNV | Missense_Mutation | novel | c.1007N>G | p.Leu336Arg | p.L336R | P01008 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A42T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SERPINC1 | SNV | Missense_Mutation | | c.79N>C | p.Trp27Arg | p.W27R | P01008 | protein_coding | deleterious(0) | possibly_damaging(0.721) | TCGA-E2-A1IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
SERPINC1 | SNV | Missense_Mutation | novel | c.176A>G | p.Glu59Gly | p.E59G | P01008 | protein_coding | tolerated(0.09) | benign(0.007) | TCGA-EW-A6SB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SERPINC1 | insertion | Nonsense_Mutation | novel | c.227_228insTTGAAGGAGTTAACAACTGAGGTGGCTATTA | p.Asn77Ter | p.N77* | P01008 | protein_coding | | | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
SERPINC1 | SNV | Missense_Mutation | rs775413132 | c.1120G>A | p.Asp374Asn | p.D374N | P01008 | protein_coding | tolerated(0.05) | probably_damaging(0.946) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SERPINC1 | SNV | Missense_Mutation | rs201541724 | c.1172G>A | p.Arg391Gln | p.R391Q | P01008 | protein_coding | tolerated(0.25) | benign(0.003) | TCGA-EA-A3QE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
462 | SERPINC1 | DRUGGABLE GENOME, PROTEASE INHIBITOR | | Unfractionated heparin | | |
462 | SERPINC1 | DRUGGABLE GENOME, PROTEASE INHIBITOR | | SULODEXIDE | SULODEXIDE | |
462 | SERPINC1 | DRUGGABLE GENOME, PROTEASE INHIBITOR | activator | CHEMBL1201476 | ENOXAPARIN SODIUM | |
462 | SERPINC1 | DRUGGABLE GENOME, PROTEASE INHIBITOR | | Sulodexide | SULODEXIDE | |
462 | SERPINC1 | DRUGGABLE GENOME, PROTEASE INHIBITOR | | FONDAPARINUX | FONDAPARINUX | |
462 | SERPINC1 | DRUGGABLE GENOME, PROTEASE INHIBITOR | | RO-14 | | |
462 | SERPINC1 | DRUGGABLE GENOME, PROTEASE INHIBITOR | | ENOXAPARIN | ENOXAPARIN | |
462 | SERPINC1 | DRUGGABLE GENOME, PROTEASE INHIBITOR | | avatrombopag | AVATROMBOPAG | |
462 | SERPINC1 | DRUGGABLE GENOME, PROTEASE INHIBITOR | | Avatrombopag | AVATROMBOPAG | |
462 | SERPINC1 | DRUGGABLE GENOME, PROTEASE INHIBITOR | | Heparin Calcium | | |